Xortx Therapeutics Stock Today
| XRTX Stock | USD 0.95 0.02 2.15% |
Performance0 of 100
| Odds Of DistressLess than 43
|
XORTX Therapeutics is trading at 0.95 as of the 31st of January 2025; that is 2.15 percent increase since the beginning of the trading day. The stock's open price was 0.93. XORTX Therapeutics has about a 43 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 1st of January 2025 and ending today, the 31st of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of November 2018 | Category Healthcare | Classification Health Care |
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. The company has 3.22 M outstanding shares of which 92.93 K shares are at this time shorted by private and institutional investors with about 0.02 trading days to cover. More on XORTX Therapeutics
Moving together with XORTX Stock
Moving against XORTX Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
XORTX Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsXORTX Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand XORTX Therapeutics' financial leverage. It provides some insight into what part of XORTX Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
XORTX Therapeutics (XRTX) is traded on NASDAQ Exchange in USA. It is located in 3710 ? 33rd Street NW, Alberta Beach, AB, Canada, T2L 2M1 and employs 2 people. XORTX Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.34 M. XORTX Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.22 M outstanding shares of which 92.93 K shares are at this time shorted by private and institutional investors with about 0.02 trading days to cover.
XORTX Therapeutics currently holds about 13.42 M in cash with (6.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check XORTX Therapeutics Probability Of Bankruptcy
Ownership AllocationXORTX Therapeutics maintains 3.01 (%) of its outstanding shares held by insiders and 6.03 (%) owned by institutional investors.
Check XORTX Ownership Details
XORTX Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-09-30 | 18.8 K | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 1.2 K | |
| Royal Bank Of Canada | 2024-09-30 | 672 | |
| Hartland & Co | 2024-09-30 | 277 | |
| Jpmorgan Chase & Co | 2024-09-30 | 254 | |
| Tower Research Capital Llc | 2024-09-30 | 84.0 | |
| Bank Of Montreal | 2024-06-30 | 0.0 | |
| Bmo Capital Markets Corp. | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 |
XORTX Therapeutics Historical Income Statement
XORTX Stock Against Markets
XORTX Therapeutics Corporate Management
| MD MBA | Chief Officer | Profile | |
| Charlotte May | Corporate Secretary | Profile | |
| MRCP MD | Chief Officer | Profile | |
| David MacDonald | Consultant Operations | Profile | |
| Nick Rigopoulos | Director Communications | Profile | |
| Allen Davidoff | CEO, Founder | Profile |
Already Invested in XORTX Therapeutics?
The danger of trading XORTX Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XORTX Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XORTX Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XORTX Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.